A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma

Grants and Contracts Details

StatusFinished
Effective start/end date9/25/076/30/14

Funding

  • Genentech Inc: $72,304.00